$CGTX
COGNITION THERAPEUTICS INC

2024 Q1 Form 10-K Financial Statement

#000155837024003949 Filed on March 26, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.549M $3.589M $13.53M
YoY Change 0.17% 25.49% 2.28%
% of Gross Profit
Research & Development $10.55M $11.60M $37.20M
YoY Change 94.35% 80.12% 22.66%
% of Gross Profit
Depreciation & Amortization $27.00K $26.00K $96.00K
YoY Change 28.57% 13.04% 15.66%
% of Gross Profit
Operating Expenses $14.10M $15.19M $50.72M
YoY Change 57.16% 63.32% 16.47%
Operating Profit -$14.10M -$50.72M
YoY Change 57.16% 16.47%
Interest Expense -$205.0K -$9.000K -$27.00K
YoY Change 1950.0% -10.0% -3.57%
% of Operating Profit
Other Income/Expense, Net $4.951M $7.057M $24.96M
YoY Change 76.76% 70.95% 12.68%
Pretax Income -$9.151M -$8.141M -$25.79M
YoY Change 48.27% 57.1% 20.59%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$9.151M -$8.141M -$25.79M
YoY Change 48.27% 57.1% 20.52%
Net Earnings / Revenue
Basic Earnings Per Share -$0.27 -$0.86
Diluted Earnings Per Share -$0.27 -$0.26 -$0.86
COMMON SHARES
Basic Shares Outstanding 39.00M 30.42M 30.03M
Diluted Shares Outstanding 33.74M 30.03M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $34.67M $29.92M $29.92M
YoY Change -10.66% -28.01% -28.01%
Cash & Equivalents $34.67M $29.92M $29.92M
Short-Term Investments
Other Short-Term Assets $2.436M $3.019M $3.019M
YoY Change 2.27% 25.11% 25.11%
Inventory
Prepaid Expenses $2.436M $3.019M
Receivables
Other Receivables
Total Short-Term Assets $37.97M $34.22M $34.22M
YoY Change -11.29% -28.18% -28.18%
LONG-TERM ASSETS
Property, Plant & Equipment $257.0K $941.0K $941.0K
YoY Change 1.58% 303.86% -10.04%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Assets $883.0K $941.0K $941.0K
YoY Change -69.15% -66.13% -66.13%
TOTAL ASSETS
Total Short-Term Assets $37.97M $34.22M $34.22M
Total Long-Term Assets $883.0K $941.0K $941.0K
Total Assets $38.85M $35.16M $35.16M
YoY Change -14.92% -30.27% -30.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.639M $3.695M $3.695M
YoY Change -15.42% 14.89% 14.89%
Accrued Expenses $4.734M $4.229M $4.229M
YoY Change 123.83% 101.96% 88.54%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.503M $10.17M $10.17M
YoY Change 27.3% 30.46% 30.46%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $520.0K $520.0K
YoY Change -100.0% -69.16% -78.16%
Total Long-Term Liabilities $0.00 $520.0K $520.0K
YoY Change -100.0% -69.16% -78.16%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.503M $10.17M $10.17M
Total Long-Term Liabilities $0.00 $520.0K $520.0K
Total Liabilities $9.991M $10.69M $10.69M
YoY Change 1.12% 5.04% 5.04%
SHAREHOLDERS EQUITY
Retained Earnings -$150.3M -$141.2M
YoY Change 23.66% 22.35%
Common Stock $40.00K $32.00K
YoY Change 37.93% 10.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $28.86M $24.47M $24.47M
YoY Change
Total Liabilities & Shareholders Equity $38.85M $35.16M $35.16M
YoY Change -14.92% -30.27% -30.27%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$9.151M -$8.141M -$25.79M
YoY Change 48.27% 57.1% 20.52%
Depreciation, Depletion And Amortization $27.00K $26.00K $96.00K
YoY Change 28.57% 13.04% 15.66%
Cash From Operating Activities -$7.244M -$5.458M -$16.02M
YoY Change 167.8% -46.41% -13.57%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $27.00K $147.0K
YoY Change -100.0% 170.0% -14.04%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$27.00K -$147.0K
YoY Change -100.0% 170.0% -14.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $5.332M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 11.99M 2.441M 4.521M
YoY Change -120030.0% -52.53% -18.48%
NET CHANGE
Cash From Operating Activities -7.244M -5.458M -16.02M
Cash From Investing Activities 0.000 -27.00K -147.0K
Cash From Financing Activities 11.99M 2.441M 4.521M
Net Change In Cash 4.749M -3.044M -11.64M
YoY Change -272.57% -39.75% -11.51%
FREE CASH FLOW
Cash From Operating Activities -$7.244M -$5.458M -$16.02M
Capital Expenditures $0.00 $27.00K $147.0K
Free Cash Flow -$7.244M -$5.485M -$16.17M
YoY Change 163.8% -46.19% -13.57%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001455365
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32165478
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28991548
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28991548
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32165478
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
true
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-40886
CY2023 dei Entity Registrant Name
EntityRegistrantName
COGNITION THERAPEUTICS, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-4365359
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
2500 Westchester Ave.
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Purchase
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10577
CY2023 dei City Area Code
CityAreaCode
412
CY2023 dei Local Phone Number
LocalPhoneNumber
481-2210
CY2023 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2023 dei Trading Symbol
TradingSymbol
CGTX
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
43124364
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
39000152
CY2023 dei Auditor Firm
AuditorFirmId
42
CY2023 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2023 dei Auditor Location
AuditorLocation
Philadelphia, PA
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29922000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41562000
CY2023Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
1281000
CY2022Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
3672000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3019000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2413000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
34222000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
47647000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
284000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
233000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
657000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
813000
CY2022Q4 us-gaap Other Assets
OtherAssets
1732000
CY2023Q4 us-gaap Assets
Assets
35163000
CY2022Q4 us-gaap Assets
Assets
50425000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3695000
CY2023 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
158000
CY2022 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-35000
CY2023 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-27000
CY2022 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-28000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
24936000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3216000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4055000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2094000
CY2023Q4 cgtx Deferred Grant Income Current
DeferredGrantIncomeCurrent
1701000
CY2022Q4 cgtx Deferred Grant Income Current
DeferredGrantIncomeCurrent
1702000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
174000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
149000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
544000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
634000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10169000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7795000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
520000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
695000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1686000
CY2023Q4 us-gaap Liabilities
Liabilities
10689000
CY2022Q4 us-gaap Liabilities
Liabilities
10176000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32165478
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28991548
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
32000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
29000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
165826000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
155820000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-141189000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-115401000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-195000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-199000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
24474000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
40249000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
35163000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50425000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37196000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30324000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13528000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13227000
CY2023 us-gaap Operating Expenses
OperatingExpenses
50724000
CY2022 us-gaap Operating Expenses
OperatingExpenses
43551000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-50724000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-43551000
CY2023 cgtx Grant Income
GrantIncome
24805000
CY2022 cgtx Grant Income
GrantIncome
22217000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
22154000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-25788000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-21397000
CY2023 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
4000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25784000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21398000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.86
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.86
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30029087
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23640199
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30029087
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23640199
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
51273000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1618000
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5184000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3572000
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-21397000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
40249000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4354000
CY2023 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
4000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-25788000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
24474000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-25788000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-21397000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
96000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
83000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
4354000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
3572000
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
156000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
152000
CY2023 cgtx Issuance Of Common Stock As Commitment Shares For Equity Line Financing
IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing
318000
CY2023 cgtx Increase Decrease In Grant Receivables
IncreaseDecreaseInGrantReceivables
-2391000
CY2022 cgtx Increase Decrease In Grant Receivables
IncreaseDecreaseInGrantReceivables
1873000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1852000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1302000
CY2022 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-467000
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2440000
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-749000
CY2023 cgtx Increase Decrease In Deferred Grant Income Current
IncreaseDecreaseInDeferredGrantIncomeCurrent
-1687000
CY2022 cgtx Increase Decrease In Deferred Grant Income Current
IncreaseDecreaseInDeferredGrantIncomeCurrent
2635000
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-150000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-121000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16018000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18533000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
147000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
171000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-147000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-171000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1618000
CY2023 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
811000
CY2022 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
1396000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4521000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5546000
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4000
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11640000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13159000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41562000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54721000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29922000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41562000
CY2023 cgtx Prepayment Of Insurance Through Third Party Financing
PrepaymentOfInsuranceThroughThirdPartyFinancing
721000
CY2022 cgtx Prepayment Of Insurance Through Third Party Financing
PrepaymentOfInsuranceThroughThirdPartyFinancing
838000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
349000
CY2022 cgtx Deferred Offering Costs Included In Accounts Payable
DeferredOfferingCostsIncludedInAccountsPayable
140000
CY2022Q4 cgtx Maximum Aggregate Offering Price
MaximumAggregateOfferingPrice
200000000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29922000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2023Q4 cgtx Allowance For Credit Loss Grants Receivable Current
AllowanceForCreditLossGrantsReceivableCurrent
0
CY2023 cgtx Grant Income
GrantIncome
24805000
CY2022 cgtx Grant Income
GrantIncome
22217000
CY2023Q4 cgtx Deferred Grant Income Current
DeferredGrantIncomeCurrent
1701000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2022Q4 cgtx Deferred Grant Income Current
DeferredGrantIncomeCurrent
1702000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1686000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company’s financial instruments that are exposed to credit risks consist of cash and cash equivalents. The Company maintains its cash and cash equivalents in bank deposit accounts which, at times, may exceed the federally insured limit. The Company has not experienced any losses in these accounts and does not believe it is exposed to any significant credit risk related to these funds.</p>
CY2023 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
4000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
29391000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
37479000
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
2.10
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4213405
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.73
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1579000
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1333000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1186000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1049000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
953000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
284000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
233000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
96000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
83000
CY2023 us-gaap Adjustment For Amortization
AdjustmentForAmortization
2000
CY2022 us-gaap Adjustment For Amortization
AdjustmentForAmortization
2000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1165000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
870000
CY2023Q4 cgtx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
2520000
CY2022Q4 cgtx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
900000
CY2023Q4 cgtx Legal Reserves Professional Fees And Other Accruals Current
LegalReservesProfessionalFeesAndOtherAccrualsCurrent
370000
CY2022Q4 cgtx Legal Reserves Professional Fees And Other Accruals Current
LegalReservesProfessionalFeesAndOtherAccrualsCurrent
324000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4055000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2094000
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1431000
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y8M12D
CY2023Q4 cgtx Operating Lease Assets
OperatingLeaseAssets
657000
CY2022Q4 cgtx Operating Lease Assets
OperatingLeaseAssets
813000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
657000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
813000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
174000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
149000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
520000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
695000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
694000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
844000
CY2023 us-gaap Operating Lease Expense
OperatingLeaseExpense
215000
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
203000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
221000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
222000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
155000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
87000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
88000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
37000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
810000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
116000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
694000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y1M6D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.081
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.081
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
209000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
172000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3012499
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.00
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32165478
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28991548
CY2023 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.9147
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9268
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.9109
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9273
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0346
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0471
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0187
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0422
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3679468
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.13
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2085000
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M12D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
628769
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.01
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
83931
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.98
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
10901
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.56
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.83
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
628769
CY2023 cgtx Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
983000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
524370
CY2022 cgtx Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
943000
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1761516
CY2023 cgtx Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue
0
CY2022 cgtx Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue
1325000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2738000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4354000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3572000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
4258000
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y7M6D
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4735560
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3679468
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
6847000
CY2023 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.06
CY2023 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
199000
CY2022 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
156000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-25767000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-21384000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-21000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-13000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-25788000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-21397000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.005
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.153
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.224
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.120
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.045
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.151
CY2023 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.032
CY2022 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.017
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.004
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.009
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
8194000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
3112000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1728000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
407000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
307000
CY2023Q4 cgtx Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
148000
CY2022Q4 cgtx Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
178000
CY2023Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
11371000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
5687000
CY2023Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
223000
CY2022Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
354000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
246000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
165000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
22354000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
16613000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
22207000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
16435000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
147000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
178000
CY2023Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
8000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
7000
CY2023Q4 cgtx Deferred Tax Liabilities Operating Lease Right Of Use Asset
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
139000
CY2022Q4 cgtx Deferred Tax Liabilities Operating Lease Right Of Use Asset
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
171000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
147000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
178000
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
5772000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-2610000

Files In Submission

Name View Source Status
0001558370-24-003949-index-headers.html Edgar Link pending
0001558370-24-003949-index.html Edgar Link pending
0001558370-24-003949.txt Edgar Link pending
0001558370-24-003949-xbrl.zip Edgar Link pending
cgtx-20231231.xsd Edgar Link pending
cgtx-20231231x10k.htm Edgar Link pending
cgtx-20231231x10k001.jpg Edgar Link pending
cgtx-20231231x10k002.jpg Edgar Link pending
cgtx-20231231x10k003.jpg Edgar Link pending
cgtx-20231231x10k004.jpg Edgar Link pending
cgtx-20231231x10k005.jpg Edgar Link pending
cgtx-20231231x10k006.jpg Edgar Link pending
cgtx-20231231x10k007.jpg Edgar Link pending
cgtx-20231231x10k008.jpg Edgar Link pending
cgtx-20231231x10k009.jpg Edgar Link pending
cgtx-20231231x10k010.jpg Edgar Link pending
cgtx-20231231x10k011.jpg Edgar Link pending
cgtx-20231231x10k012.jpg Edgar Link pending
cgtx-20231231x10k013.jpg Edgar Link pending
cgtx-20231231x10k014.jpg Edgar Link pending
cgtx-20231231x10k015.jpg Edgar Link pending
cgtx-20231231x10k016.jpg Edgar Link pending
cgtx-20231231x10k017.jpg Edgar Link pending
cgtx-20231231x10k018.jpg Edgar Link pending
cgtx-20231231x10k019.jpg Edgar Link pending
cgtx-20231231x10k020.jpg Edgar Link pending
cgtx-20231231x10k021.jpg Edgar Link pending
cgtx-20231231xex21d1.htm Edgar Link pending
cgtx-20231231xex23d1.htm Edgar Link pending
cgtx-20231231xex31d1.htm Edgar Link pending
cgtx-20231231xex31d2.htm Edgar Link pending
cgtx-20231231xex32d1.htm Edgar Link pending
cgtx-20231231xex32d2.htm Edgar Link pending
cgtx-20231231xex97d1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
cgtx-20231231_lab.xml Edgar Link unprocessable
cgtx-20231231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cgtx-20231231x10k_htm.xml Edgar Link completed
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cgtx-20231231_def.xml Edgar Link unprocessable
cgtx-20231231_cal.xml Edgar Link unprocessable